Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 117.53 Million KRW | -99.9% |
| 2022 | 118.32 Billion KRW | 12.43% |
| 2021 | 105.24 Billion KRW | 743.13% |
| 2020 | 12.48 Billion KRW | -69.66% |
| 2019 | 41.13 Billion KRW | -29.71% |
| 2018 | 58.52 Billion KRW | 2.69% |
| 2017 | 56.98 Billion KRW | -44.59% |
| 2016 | 102.84 Billion KRW | -7.94% |
| 2015 | 111.71 Billion KRW | 47.39% |
| 2014 | 75.79 Billion KRW | -31.97% |
| 2013 | 111.41 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 11.01 Billion KRW | 228.18% |
| 2024 Q1 | 3.35 Billion KRW | 2755.27% |
| 2023 Q2 | 91.17 Billion KRW | -1.98% |
| 2023 Q1 | 93 Billion KRW | -21.39% |
| 2023 FY | 117.53 Million KRW | -99.9% |
| 2023 Q4 | 117.53 Million KRW | 102.43% |
| 2023 Q3 | -4.82 Billion KRW | -105.3% |
| 2022 Q3 | 134.19 Billion KRW | 8.81% |
| 2022 Q2 | 123.33 Billion KRW | -6.37% |
| 2022 FY | 118.32 Billion KRW | 12.43% |
| 2022 Q1 | 131.73 Billion KRW | 25.17% |
| 2022 Q4 | 118.32 Billion KRW | -11.83% |
| 2021 Q1 | 12.05 Billion KRW | -3.4% |
| 2021 Q4 | 105.24 Billion KRW | 638.54% |
| 2021 FY | 105.24 Billion KRW | 743.13% |
| 2021 Q3 | 14.24 Billion KRW | -0.33% |
| 2021 Q2 | 14.29 Billion KRW | 18.58% |
| 2020 Q2 | 11.3 Billion KRW | -63.96% |
| 2020 Q3 | 20.21 Billion KRW | 78.91% |
| 2020 FY | 12.48 Billion KRW | -69.66% |
| 2020 Q1 | 31.35 Billion KRW | -23.77% |
| 2020 Q4 | 12.48 Billion KRW | -38.27% |
| 2019 FY | 41.13 Billion KRW | -29.71% |
| 2019 Q1 | 46.91 Billion KRW | -19.83% |
| 2019 Q4 | 41.13 Billion KRW | 41.61% |
| 2019 Q3 | 29.04 Billion KRW | -42.16% |
| 2019 Q2 | 50.22 Billion KRW | 7.04% |
| 2018 Q2 | 88.63 Billion KRW | 48.04% |
| 2018 FY | 58.52 Billion KRW | 2.69% |
| 2018 Q4 | 58.52 Billion KRW | -25.32% |
| 2018 Q3 | 78.36 Billion KRW | -11.59% |
| 2018 Q1 | 59.87 Billion KRW | 5.06% |
| 2017 FY | 56.98 Billion KRW | -44.59% |
| 2017 Q4 | 56.98 Billion KRW | 0.0% |
| 2016 Q2 | 145.9 Billion KRW | 28.09% |
| 2016 Q1 | 113.9 Billion KRW | 1.96% |
| 2016 FY | 102.84 Billion KRW | -7.94% |
| 2016 Q3 | 136.89 Billion KRW | -6.17% |
| 2015 Q2 | 85.53 Billion KRW | 30.89% |
| 2015 Q4 | 111.71 Billion KRW | 28.64% |
| 2015 Q1 | 65.34 Billion KRW | -13.79% |
| 2015 Q3 | 86.83 Billion KRW | 1.53% |
| 2015 FY | 111.71 Billion KRW | 47.39% |
| 2014 Q2 | 79.06 Billion KRW | 9.59% |
| 2014 Q1 | 72.14 Billion KRW | 0.0% |
| 2014 Q3 | 69.6 Billion KRW | -11.97% |
| 2014 FY | 75.79 Billion KRW | -31.97% |
| 2014 Q4 | 75.79 Billion KRW | 8.9% |
| 2013 FY | 111.41 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 98.665% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 99.979% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 99.962% |
| HANDOK Inc. | 283.45 Billion KRW | 99.959% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 99.414% |
| Yuhan Corporation | -69.18 Billion KRW | 100.17% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 99.939% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 103.189% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 99.977% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 100.362% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 99.845% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 99.681% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 99.858% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 99.532% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 98.665% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 100.074% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 99.942% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 99.931% |
| JW Holdings Corporation | 480.68 Billion KRW | 99.976% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 99.929% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 99.924% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 95.001% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 99.489% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 99.933% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 99.774% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 98.665% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 99.926% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 99.967% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 99.924% |
| Yuhan Corporation | -69.18 Billion KRW | 100.17% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 99.914% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 99.803% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 99.973% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 99.924% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 99.899% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 99.284% |
| CKD Bio Corp. | 143.29 Billion KRW | 99.918% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 99.899% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 100.488% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 100.263% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 95.001% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 99.972% |
| Boryung Corporation | 187.72 Billion KRW | 99.937% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 100.164% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 99.845% |
| JW Lifescience Corporation | 26.09 Billion KRW | 99.55% |